MLLStart! advised Clinical Research Ventures in its investment into BioVersys 

MLLStart! advised Clinical Research Ventures (CR Ventures), a Singapore, Frankfurt and Boston based global life-science investor with a focus on companies entering Phase I or II clinical trials in its investment into BioVersys, Basel, a biotech company focusing on research and development of small molecules which switch off drug resistance against antibiotics. The investment forms part of the recently closed series B round and will allow BioVersys to advance its two lead assets for multi-drug resistant bacterial infections through initial clinical trials. In November BioVersys announced it had successfully dosed the first patients in its phase I trial with BV100.

The team 

The team was led by Senior Associate Marco Fusi (Transaction/M&A & Venture Capital – pictured) and supported by Karin Oberlin (Partner, Transaction/M&A & Venture Capital) and included Julian Kläser (Senior Associate, Tax) and Göktug Gürbüz (Junior Associate).

MLLStart! advised Clinical Research Ventures in its investment into BioVersys 


Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram